Beacon Pointe Advisors LLC Buys Shares of 8,911 Medpace Holdings, Inc. $MEDP

Beacon Pointe Advisors LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,911 shares of the company's stock, valued at approximately $4,719,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Johnson Financial Group Inc. bought a new position in shares of Medpace during the second quarter valued at $27,000. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp acquired a new stake in Medpace in the second quarter valued at $30,000. Finally, Allied Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at $31,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

Shares of MEDP opened at $600.65 on Friday. The firm has a market cap of $16.77 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The business's 50 day moving average price is $565.33 and its two-hundred day moving average price is $494.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian T. Carley sold 5,000 shares of the business's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares of the company's stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 133,821 shares of company stock worth $81,748,135 over the last three months. 20.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MEDP. Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a research note on Thursday, July 23rd. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, Medpace has an average rating of "Hold" and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source